Literature DB >> 15973455

Insights into the multistep transformation process of lymphomas: IgH-associated translocations and tumor suppressor gene mutations in clonally related composite Hodgkin's and non-Hodgkin's lymphomas.

R Schmitz1, C Renné, R Rosenquist, M Tinguely, V Distler, F Menestrina, M Lestani, T Stankovic, B Austen, A Bräuninger, M-L Hansmann, R Küppers.   

Abstract

Clonally related composite lymphomas of Hodgkin's lymphoma (HL) and Non-Hodgkin's lymphoma (NHL) represent models to study the multistep transformation process in tumorigenesis and the development of two distinct tumors from a shared precursor. We analyzed six such lymphomas for transforming events. The HLs were combined in two cases with follicular lymphoma (FL), and in one case each with B-cell chronic lymphocytic leukemia, splenic marginal zone lymphoma, mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL). In the HL/FL and HL/MCL combinations, BCL2/IGH and CCND1/IGH translocations, respectively, were detected in both the HL and NHL. No mutations were found in the tumor suppressor genes FAS, NFKBIA and ATM. The HL/DLBCL case harbored clonal replacement mutations of the TP53 gene on both alleles exclusively in the DLBCL. In conclusion, we present the first examples of molecularly verified IgH-associated translocations in HL, which also show that BCL2/IGH or CCND1/IGH translocations can represent early steps in the pathogenesis of composite HL/FL or HL/MCL. The restriction of the TP53 mutations to the DLBCL in the HL/DLBCL case exemplifies a late transforming event that presumably happened in the germinal center and affected the fate of a common lymphoma precursor cell towards development of a DLBCL. Leukemia (2005) 19, 1452-1458.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15973455     DOI: 10.1038/sj.leu.2403841

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  12 in total

Review 1.  [Role of cytology in hematopathological diagnostics].

Authors:  B Bode; M Tinguely
Journal:  Pathologe       Date:  2012-07       Impact factor: 1.011

2.  Three coexisting lymphomas in a single patient: composite lymphoma derived from a common germinal center B-cell precursor and unrelated discordant lymphoma.

Authors:  Atsujiro Nishioka; Hiroshi Ureshino; Toshihiko Ando; Haruna Kizuka; Kana Kusaba; Haruhiko Sano; Hidekazu Itamura; Yasushi Kubota; Kensuke Kojima; Koichi Ohshima; Shinya Kimura
Journal:  Int J Hematol       Date:  2017-11-25       Impact factor: 2.490

Review 3.  Molecular pathogenesis of Hodgkin lymphoma.

Authors:  Momoko Nishikori; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

Review 4.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.

Authors:  Elias Campo; Steven H Swerdlow; Nancy L Harris; Stefano Pileri; Harald Stein; Elaine S Jaffe
Journal:  Blood       Date:  2011-02-07       Impact factor: 22.113

Review 5.  Lymphoma stem cells: enough evidence to support their existence?

Authors:  Jose A Martinez-Climent; Lorena Fontan; Randy D Gascoyne; Reiner Siebert; Felipe Prosper
Journal:  Haematologica       Date:  2010-02       Impact factor: 9.941

6.  Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features.

Authors:  Luan Nguyen; Arne Van Hoeck; Edwin Cuppen
Journal:  Nat Commun       Date:  2022-07-11       Impact factor: 17.694

7.  Discovery platform for inhibitors of IgH gene enhancer activity.

Authors:  Nathan G Dolloff
Journal:  Cancer Biol Ther       Date:  2018-11-27       Impact factor: 4.742

Review 8.  Composite lymphoma in the anterior mediastinum: a case report and review of the literature.

Authors:  Guohua Yu; Lingling Kong; Guimei Qu; Qian Zhang; Wei Wang; Lei Jiang
Journal:  Diagn Pathol       Date:  2011-07-06       Impact factor: 2.644

9.  Identification of networks of co-occurring, tumor-related DNA copy number changes using a genome-wide scoring approach.

Authors:  Christiaan Klijn; Jan Bot; David J Adams; Marcel Reinders; Lodewyk Wessels; Jos Jonkers
Journal:  PLoS Comput Biol       Date:  2010-01-01       Impact factor: 4.475

10.  A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors.

Authors:  Anthony W Tolcher; Wendi V Rodrigueza; Drew W Rasco; Amita Patnaik; Kyriakos P Papadopoulos; Alex Amaya; Timothy D Moore; Shari K Gaylor; Charles L Bisgaier; Mina P Sooch; Michael J Woolliscroft; Richard A Messmann
Journal:  Cancer Chemother Pharmacol       Date:  2013-12-03       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.